Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM versus SC concomitant administration of M-M-R II (rHA) and VARIVAX in toddlers
2004-002586-21Phase 3Completed
- Sponsor
- Aventis Pasteur MSD SNC
- Start
- Nov 2004
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Live Biotherapeutic Products → Microbiome Therapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of M-M-R II and varicella virus vaccine live in measles, mumps, rubella and 1 more (2 arms), sponsored by Aventis Pasteur MSD SNC. Primary endpoints: Response rate to measles at Day 42, Response rate to mumps at Day 42 and 3 more. Started Nov 2004; status: completed.
02
Drugs
M-M-R IIvaricella virus vaccine live
03
Conditions
measlesmumpsrubellachickenpox
Beyond the preview
Go deeper on 2004-002586-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002586-21.